Shareholders of Seres Therapeutics Inc. (NASDAQ:MCRB) were reeling back in late September 2024 after the board turned down a lucrative takeover offer from Nestlé S. A., which had aimed to acquire the company at a price between $6.00 and $6.50 per share. Given that Seres' stock closed at just $0.83 before the announcement, this rejection sparked outrage among investors who perceived it as a glaring misstep.
The context here is crucial: right around this time, Seres was moving ahead with plans to sell its VOWST business, a decision that has only compounded investor frustrations. Lucien Selce and MKT Capital Ltd., who collectively hold about 1.4 million shares, have publicly demanded clarification regarding why the board passed on what many saw as an advantageous deal while simultaneously opting for asset divestment.
Nestlé Offer Ignored: The Financial Fallout
This whole situation exposed some serious financial headaches for Seres. With their stock already volatile—having dropped from $1.28 post-VOWST sale announcement—the optics of rejecting such a high-premium bid sent alarm bells ringing throughout their investor base. How could they let go of that? It’s a head-scratcher when you consider how deeply in the red the company was, reporting staggering losses and an operating income of -$157.87 million.
“The missed Nestlé acquisition opportunity is leaving shareholders questioning the board’s strategy,” said one frustrated investor.
The looming question now revolves around transparency—or lack thereof—from Seres’ management team as shareholders look for answers regarding how decisions are being made amidst these turbulent times.
